Global Ultrasound Tumor Therapy System (HIFU) Market Strategic Research Report

Scope of the Report

The global Ultrasound Tumor Therapy System (HIFU) market size is predicted to grow from US$ 149 million in 2025 to US$ 240 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.

Ultrasonic tumor treatment system is a high-intensity focused ultrasound HIFU device, which is mainly composed of a main unit (energy table) and a treatment bed. It mainly uses ultrasound as an energy source, and uses its penetrability and focusability to focus the external ultrasound on the lesions in the body, and directly kills the tumor tissue through instantaneous high temperature. The clinical advantages of the ultrasonic tumor treatment system are mainly that there is no surgical incision, avoiding the radiation damage of traditional radiotherapy or the systemic toxicity of chemotherapy; with micron-level precision, it can treat deep tissues.

Ultrasonic tumor treatment systems are gradually changing the traditional tumor treatment landscape with their core advantages of being non-invasive, precise (focal error ≤ 3mm) and fast recovery (1-3 days after surgery). They use high-intensity focused ultrasound (HIFU) to target and ablate lesions, avoiding surgical trauma and the toxic side effects of radiotherapy and chemotherapy. They are particularly suitable for complex scenarios such as uterine fibroids (effectiveness exceeds 95%), prostate cancer and deep bone tumors (penetration depth of more than 15cm). In terms of companies, the JC series of equipment from Chinese local manufacturer Haifu Medical leads the world; international manufacturers focus on differentiated tracks - Israel's Insightec's Exablate Neuro system has passed FDA certification and specializes in Parkinson's tremor and brain tumor treatment, and the US Sonablate's equipment accurately ablates prostate cancer through the transrectal route.

Future trends revolve around breakthroughs in three major directions: ​Intelligence​ (AI target area delineation + robot positioning), combined therapy​ (HIFU+immunotherapy activates systemic anti-tumor effects) and portability​. Although the current device penetration rate is less than 5%, with policy support and technology iteration, the global market size is expected to exceed US$200 million in 2030.

This report presents a comprehensive overview of the global Ultrasound Tumor Therapy System (HIFU) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Mobile Therapy System
• Fixed Therapy System

Segment by Application

• Liver Cancer
• Breast Cancer
• Prostate Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Ultrasound Tumor Therapy System (HIFU) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Liver Cancer, Breast Cancer, Prostate Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact